The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Klaus Podar

Dana-Farber Cancer Institute

Jerome Lipper Multiple Myeloma Center

Department of Medical Oncology

Boston

USA

[email]@*.harvard.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Dana-Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Boston, USA. 2009
  • Department of Medical Oncology, LeBow Institute for Myeloma Therapeutics, Dana Farber Cancer Institute, Jerome Lipper Multiple Myeloma Center, USA. 2009
  • Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA. 2005 - 2009
  • Department of Medical Oncology, Jerome Lipper Multiple Myeloma Center, Harvard Medical School, Dana-Farber Cancer Institute, USA. 2008

References

  1. Emerging therapies for multiple myeloma. Podar, K., Tai, Y.T., Hideshima, T., Vallet, S., Richardson, P.G., Anderson, K.C. Expert. Opin. Emerg. Drugs (2009) [Pubmed]
  2. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Podar, K., Chauhan, D., Anderson, K.C. Leukemia (2009) [Pubmed]
  3. A pivotal role for Mcl-1 in Bortezomib-induced apoptosis. Podar, K., Gouill, S.L., Zhang, J., Opferman, J.T., Zorn, E., Tai, Y.T., Hideshima, T., Amiot, M., Chauhan, D., Harousseau, J.L., Anderson, K.C. Oncogene (2008) [Pubmed]
  4. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Podar, K., Raab, M.S., Zhang, J., McMillin, D., Breitkreutz, I., Tai, Y.T., Lin, B.K., Munshi, N., Hideshima, T., Chauhan, D., Anderson, K.C. Blood (2007) [Pubmed]
  5. The malignant clone and the bone-marrow environment. Podar, K., Richardson, P.G., Hideshima, T., Chauhan, D., Anderson, K.C. Best. Pract. Res. Clin. Haematol (2007) [Pubmed]
  6. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Podar, K., Raab, M.S., Tonon, G., Sattler, M., Barilà, D., Zhang, J., Tai, Y.T., Yasui, H., Raje, N., DePinho, R.A., Hideshima, T., Chauhan, D., Anderson, K.C. Cancer Res. (2007) [Pubmed]
  7. The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Podar, K., Raab, M.S., Chauhan, D., Anderson, K.C. Expert. Opin. Investig. Drugs (2007) [Pubmed]
  8. Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Podar, K., Anderson, K.C. Cell. Cycle (2007) [Pubmed]
  9. Targeting the vascular endothelial growth factor pathway in the treatment of multiple myeloma. Podar, K., Richardson, P.G., Chauhan, D., Anderson, K.C. Expert. Rev. Anticancer. Ther (2007) [Pubmed]
  10. Caveolin-1 as a potential new therapeutic target in multiple myeloma. Podar, K., Anderson, K.C. Cancer Lett. (2006) [Pubmed]
  11. Targeting signalling pathways for the treatment of multiple myeloma. Podar, K., Hideshima, T., Chauhan, D., Anderson, K.C. Expert Opin. Ther. Targets (2005) [Pubmed]
 
WikiGenes - Universities